The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TIGOS-LS, an open-label, randomized study of BMS-986489 vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer.
 
Melissa Johnson
Consulting or Advisory Role - Abbvie (Inst); Alentis Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Biohaven Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Hookipa Biotech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); ModeX Therapeutics (Inst); Normunity (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sanofi (Inst); SeaGen (Inst); Synthekine (Inst); Takeda (Inst); Zai Lab (Inst)
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); ArriVent Biopharma (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); City of Hope (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EQRx (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immuneering (Inst); Immunitas (Inst); Immunocore (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Lilly (Inst); LockBody Therapeutics (Inst); Loxo (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); Mythic Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Nextpoint (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoC4 (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scorpion Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Summit Therapeutics (Inst); Syndax (Inst); Systimmune (Inst); Taiho Oncology (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); TheRas (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); Vividion Therapeutics (Inst); Vyriad (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Ticiana Leal
Consulting or Advisory Role - Abbvie; Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; BMS GmbH & Co. KG; Catalyst Pharmaceuticals; Catalyst Pharmaceuticals; Genentech; Janssen; Jazz Pharmaceuticals; Novartis; Novocure; Novocure; Novocure; Novocure; OncoC4; Pfizer; Regeneron; Regeneron; Roche; Sanofi; Takeda; Takeda
Research Funding - Daiichi Sankyo/Astra Zeneca (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Regeneron; Sanofi
 
Jerome Goldschmidt
Employment - Blue Ridge Cancer Care; Ontada/McKesson
 
Sarah Wang
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; EMD Serono; Oncohost
Travel, Accommodations, Expenses - Daiichi Sankyo
 
William Brady
Employment - Sarah Cannon Research Institute
Stock and Other Ownership Interests - Apellis Pharmaceuticals
 
Maen Hussein
Consulting or Advisory Role - Abbvie; Aptitude Health; Aptitude Health; Aptitude Health; AstraZeneca; AstraZeneca; AstraZeneca; Athenex; AVEO; BeiGene; BMS; BMS; Coherus Biosciences; CTI BioPharma Corp; CTI BioPharma Corp; Exelixis; G1 Therapeutics; IntegraConnect; IntegraConnect; IntrinsiQ; ipsen; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Mirati Therapeutics; National Community Oncology Dispensing Association (NCODA); oncocyte
 
Caressa Lietman
Employment - Sarah Cannon Research Institute
Stock and Other Ownership Interests - HCA Healthcare; McKesson
 
Hillarie Windish
Employment - Sarah Cannon Research Institute
Stock and Other Ownership Interests - McKesson
Research Funding - Sarah Cannon Research Institute
 
Christophe Calvet
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Invectys
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Lola Dosunmu
Employment - McKesson
Stock and Other Ownership Interests - HCA Healthcare
 
Alisha Maniar
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Novo Nordisk
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
LaRee Tracy
Employment - Bristol Myers Squibb; Moderna Therapeutics
Stock and Other Ownership Interests - Bristol Myers Squibb; Moderna Therapeutics
Travel, Accommodations, Expenses - Bristol Myers Squibb; Moderna Therapeutics
 
Neal Ready
Honoraria - Jazz Pharmaceuticals
Consulting or Advisory Role - Abbvie; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Celgene; G1 Therapeutics; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Merck; Merck Serono; Novartis; Pfizer; Regeneron; Regeneron; Sanofi/Regeneron; Zai Lab
Speakers' Bureau - Bristol-Myers Squibb; Jazz Pharmaceuticals
Research Funding - Memgen (Inst); Merck; Regeneron (Inst)